每经AI快讯，和铂医药-B(02142.HK)涨超6%，截至发稿，涨6.35%，报13.23港元，成交额993.94万港 元。 ...

消息面上，据和铂医药官微消息，10月25日，和铂医药-阿斯利康创新实验室在北京正式揭牌，标志着 双方合作进一步深化，新一代抗体药物从发现到优化的全流程研发进入"加速通道"。至此，双方已形 成"研发合作+股权投资+建立北京创新中心"的多元化合作模式，为创新药物研发注入全新动能。 据介绍，今年3月，和铂医药与阿斯利康达成全球战略合作，共同研发针对免疫性疾病、肿瘤及其他多 种疾病的新一代多特异性抗体疗法，并在北京建设创新实验室，推动前沿科研落地。经过数月筹备，该 创新实验室全面就绪，和铂医药抗体药物创新开发平台与AI干湿实验室平台已完成搭建，即将正式投 入使用，助力多领域新一代治疗性抗体研发。 和铂医药-B(02142)涨超6%，截至发稿，涨6.35%，报13.23港元，成交额993.94万港元。 ...

据介绍，今年3月，和铂医药与阿斯利康达成全球战略合作，共同研发针对免疫性疾病、肿瘤及其他多 种疾病的新一代多特异性抗体疗法，并在北京建设创新实验室，推动前沿科研落地。经过数月筹备，该 创新实验室全面就绪，和铂医药抗体药物创新开发平台与AI干湿实验室平台已完成搭建，即将正式投 入使用，助力多领域新一代治疗性抗体研发。 智通财经APP获悉，和铂医药-B(02142)涨超6%，截至发稿，涨6.35%，报13.23港元，成交额993.94万港 元。 消息面上，据和铂医药官微消息，10月25日，和铂医药-阿斯利康创新实验室在北京正式揭牌，标志着 双方合作进一步深化，新一代抗体药物从发现到优化的全流程研发进入"加速通道"。至此，双方已形 成"研发合作+股权投资+建立北京创新中心"的多元化合作模式，为创新药物研发注入全新动能。 ...

Core Insights - The establishment of the Harbour Medicine-AstraZeneca Innovation Laboratory marks a significant milestone in the strategic collaboration between the two companies, combining research and development, equity investment, and the creation of an innovation center in Beijing [2][3] - The collaboration will focus on developing innovative therapies, particularly in oncology and autoimmune diseases, leveraging Harbour Medicine's antibody technology and AstraZeneca's expertise in disease biology and clinical development [2][3] Group 1 - The innovation laboratory is described as a strategic hub that integrates Harbour Medicine's fully human antibody technology with AstraZeneca's strengths in various fields, aiming to produce more innovative results [2] - The partnership will enable an efficient relay of discovery and development processes, with Harbour Medicine responsible for early-stage research and AstraZeneca leading global development and commercialization [2][3] Group 2 - The newly established Beijing Innovation Center will utilize local resources to enhance global partnerships and integrate the Harbour Mice antibody technology platform with cutting-edge research demands [3] - Harbour Medicine has formed collaborations with several multinational pharmaceutical companies, including AstraZeneca, Pfizer, and Moderna, with a cumulative total exceeding $10 billion [3] - The collaboration with AstraZeneca has evolved from a single licensing agreement to a more integrated ecosystem approach, with previous successful projects laying a foundation for deeper strategic cooperation [3]

Core Insights - The establishment of the Harbour Mice-AstraZeneca Innovation Laboratory in Beijing marks a significant milestone in the collaboration between Harbour Mice and AstraZeneca, creating a diversified cooperation model that includes R&D collaboration, equity investment, and the establishment of an innovation center [1][3][5] Group 1: Collaboration and Innovation - The partnership aims to develop next-generation multi-specific antibody therapies targeting immune diseases, tumors, and other conditions, leveraging advanced technologies and resources [3][5] - The newly unveiled innovation laboratory integrates Harbour Mice's fully human antibody technology with AstraZeneca's expertise in disease biology, clinical development, and AI drug design, serving as a strategic hub for innovation [5][6] - The collaboration has evolved from a single licensing agreement to a comprehensive ecosystem-building approach, enhancing trust and cooperation between the two companies [7] Group 2: Technological Advancements - Harbour Mice's antibody technology platform, including the Harbour Mice and HCAb PLUS™ systems, addresses traditional challenges in antibody development, enabling the creation of fully human antibodies and expanding applications to bispecific antibodies, ADCs, CAR-T, RNA therapies, and AI [6][7] - The integration of AI and big data into the antibody development process is expected to significantly accelerate the research and development of new therapeutic antibodies [7][8] Group 3: Future Outlook - Harbour Mice plans to expand its pipeline from 5 to over 20 products, covering various therapeutic areas such as oncology, inflammation, metabolic diseases, and central nervous system disorders [8] - The company aims to strengthen its innovation capabilities and deepen platform empowerment, positioning itself as a key player in the global pharmaceutical innovation chain [8]

格隆汇10月23日丨和铂医药-B(02142.HK)公告，10月23日耗资247万港元回购20万股。 ...

智通财经APP讯，和铂医药-B(02142)发布公告，于2025年10月23日，该公司斥资247.26万港元回购20万 股股份，每股回购价格为12.14-12.48港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 第 1 頁 共 7 頁 v 1.3.0 FF305 | 於下列日期結束時的結存 (註5及6) 2025年10月23日 | | 870,615,722 | | 22,687,000 | | | 893,302,722 | | --- | --- | --- | --- | --- | --- | --- | --- | | B. 贖回/購回股份 (擬註銷但截至期終結存日期尚未註銷) (註5及6) | | | | | | | | | 購回股份（擬註銷但尚未註銷） | 1). | 250,000 | 0.0327 % | | HKD | 2.25 | | | 變動日期 | 2025年1月8日 | | | | | | | | 購回股份（擬註銷但尚未註銷） | 2). | 156,000 | 0.0204 % | | HKD | 2.39468 | | | 2025年1月10日 | 變動日期 | | | | | | | 呈交日期： 2025年10 ...

Core Viewpoint - On October 22, 35 Hong Kong-listed companies conducted share buybacks, totaling 10.4965 million shares and an amount of 52.7745 million HKD [1][2]. Group 1: Buyback Details - The company with the highest buyback amount on October 22 was AAC Technologies, with a buyback amount of 11.9098 million HKD for 300,000 shares [1][2]. - Linklogis Technology-W followed with a buyback of 2.430 million shares, amounting to 7.4708 million HKD [1][2]. - Mengniu Dairy repurchased 500,000 shares for 7.1714 million HKD [1][2]. Group 2: Year-to-Date Buyback Totals - AAC Technologies has conducted multiple buybacks this year, with a cumulative buyback amount of 858.628 million HKD [2]. - Linklogis Technology-W's total buyback amount for the year reached 225.0668 million HKD [2]. - Mengniu Dairy's year-to-date buyback amount stands at 45.832 million HKD [2]. Group 3: Buyback Volume Rankings - The highest number of shares repurchased on October 22 was by Linklogis Technology-W, with 2.43 million shares [1][2]. - Other notable buybacks in terms of volume included MorningX Technology with 1.064 million shares and China Hengyou Group with 1 million shares [1][2].

Summary of Key Points Core Viewpoint - A total of 30 companies, including major players like 瑞声科技 (AAC Technologies) and 蒙牛乳业 (Mengniu Dairy), conducted share buybacks on October 22, 2025, indicating a trend of companies returning capital to shareholders amidst market conditions. Group 1: Buyback Details - 瑞声科技 (AAC Technologies) had the largest buyback amount, repurchasing 300,000 shares for a total of 11.90 million yuan [1] - 联易融科技-W (Lianyi Technology) repurchased 2.43 million shares, totaling 7.47 million yuan, representing 3.288% of its total share capital [2] - 蒙牛乳业 (Mengniu Dairy) bought back 500,000 shares for 7.17 million yuan, which is 0.517% of its total share capital [2] Group 2: Other Notable Buybacks - 康臣药业 (Kangchen Pharmaceutical) repurchased 283,000 shares for 4.33 million yuan, accounting for 7.969% of its total share capital [2] - 连连数字 (Lianlian Digital) bought back 440,000 shares for 3.54 million yuan, which is 0.138% of its total share capital [2] - 固生堂 (Gushengtang) repurchased 91,300 shares for 2.75 million yuan, representing 2.076% of its total share capital [2] Group 3: Additional Companies Involved - 绿城服务 (Greentown Service) repurchased 216,000 shares for 989,300 yuan, which is 0.007% of its total share capital [2] - 歌礼制药-B (Galactico Pharmaceutical) bought back 100,000 shares for 926,500 yuan, accounting for 0.068% of its total share capital [2] - 医渡科技 (Yidu Technology) repurchased 17,700 shares for 99,800 yuan, representing 0.330% of its total share capital [2]